Strive Announces $1.0 Billion SATS At-The-Market Program

Strive entered into a sales agreement allowing it to issue and sell up to $1.0 billion in aggregate offering value of its 15.00% Series A Perpetual SATS Preferred Stock through an at-the-market program. The announcement provides no details on shares sold or proceeds raised.

Analysis

The $1.0bn figure is an authorization ceiling, not committed funding. An ATM can be drawn gradually and may raise less—or nothing—depending on investor demand and market conditions. If fully issued at the stated 15% rate, the preferred would carry up to $150m of annual distributions before considering issuance costs; the key test for ASST common holders is whether the proceeds earn an adequate return after that fixed economic hurdle. Preferred issuance avoids direct common-share dilution, but adds a senior claim on cash flows and can dilute the common equity’s residual value. The perpetual structure removes a stated maturity wall, but does not remove the recurring distribution burden.

Near term, watch the preferred’s actual issuance pace and pricing: a large authorization alone is not a cash-flow catalyst, while discounted or rapid issuance could signal funding pressure or weak demand. Over 1–3 months, proceeds and deployment will matter more than the headline capacity. Over 6–18 months, the outcome turns on whether returns from the funded activity exceed the preferred cost and whether distributions remain supportable. The contrarian point is that investors may overread the headline capacity as capital already raised; equally, the 15% rate makes this more than benign financing flexibility. Terms not provided—including distribution cumulativity, redemption rights, and use of proceeds—need verification.

Key Decisions for Investors

• No directional ASST trade on the announcement alone. Treat the ATM as optional financing capacity, not realized proceeds or a committed capital raise.
• Monitor actual SATS issuance volume and net proceeds, preferred-market pricing, and the stated use of funds. Reassess ASST if issuance accelerates or prices materially below stated terms.
• Before underwriting the common, verify the preferred’s full terms and whether proceeds can generate returns above the 15% distribution burden; do not assume the distributions are cumulative or that proceeds fund any particular activity.
• Falsification / risk trigger: a credible deployment plan with returns comfortably supporting the preferred cost would reduce the funding-overhang concern; weak demand, discounted issuance, or evidence distributions strain cash generation would strengthen it.